Area of research
Neurology · Cellular and Molecular Neuroscience
Research interest
Research interests include Parkinson's Disease Mechanisms and Treatments, Neurological disorders and treatments, Genetic Neurodegenerative Diseases, and HIV Research and Treatment.
<i>LRRK2</i> -associated parkinsonism with and without <i>in vivo</i> evidence of alpha-synuclein aggregates: longitudinal clinical and biomarker characterization
Safety and efficacy of continuous subcutaneous levodopa–carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial
Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson’s Disease: The International Linked Clinical Trials Initiative
Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial
Trichloroethylene: An Invisible Cause of Parkinson’s Disease?
Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson’s Disease Progression
Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial
Remote smartphone monitoring of Parkinson’s disease and individual response to therapy
Subcutaneous Levodopa Infusion for Parkinson's Disease: 1<scp>‐Year</scp> Data from the <scp>Open‐Label BeyoND</scp> Study
Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression
The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort
Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort
Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls
Education and training of clinical and translational study investigators and research coordinators: A competency-based approach
Enhancing Clinical Research Professionals’ Training and Qualifications (ECRPTQ): Recommendations for Good Clinical Practice (GCP) training for investigators and study coordinators
CSF biomarkers associated with disease heterogeneity in early Parkinson’s disease: the Parkinson’s Progression Markers Initiative study
A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease
A randomized trial of inhaled levodopa (CVT‐301) for motor fluctuations in Parkinson's disease
A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease
Quality of life in idiopathic intracranial hypertension at diagnosis
Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS)
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Inosine to Increase Serum and Cerebrospinal Fluid Urate in Parkinson Disease
Are therapeutic motivation and having one's own doctor as researcher sources of therapeutic misconception?
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study
Factors predictive of the development of Levodopa‐induced dyskinesia and wearing‐off in Parkinson's disease
Comparison of enrollees and decliners of Parkinson disease sham surgery trials